Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
about
Clinical immunologic approaches for the treatment of Alzheimer's diseaseIntravenous immunoglobulin and Alzheimer's disease: what now?Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chainsImmunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.Anti-amyloidogenic activity of IgGs contained in normal plasmaAmyloid-beta immunotherapy for Alzheimer's diseaseHuman intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseIntravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsBeta-amyloid auto-antibodies are reduced in Alzheimer's disease.Human B-1 cells take the stage.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia.Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.Novel strategies for Alzheimer's disease treatment.Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.Antibody-based therapy in Alzheimer's disease.Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunomodulation and AD--down but not out.AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.Animal Models of Alzheimer's Disease: Utilization of Transgenic Alzheimer's Disease Models in Studies of Amyloid Beta Clearance.Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.Vaccination strategies in tauopathies and synucleinopathies.A neuroimmunologist's perspective on Alzheimer's disease therapy.Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease.Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein
P2860
Q22241380-C8231203-4D23-4962-B6FF-E46AEBBDE8D2Q27000371-3529F68F-A70F-4E96-83AD-253BEFD63208Q33392254-A18DEB45-866D-4311-A8B1-A565CB5F7FCAQ33569608-91CB1065-700F-475B-BD64-8CD64804B2BDQ33573668-171E1692-0677-4C5A-AAE7-886CBCD07A4AQ33903503-9DF0C2EF-4B3E-4125-8E36-E15AB825F7B0Q33954737-D8AE9C5E-FE3D-49ED-A782-0DB46112DFB3Q34419295-9729A183-B304-4540-B0B5-631F1AC08D82Q34733689-3260FF2A-6DBB-48CB-99BF-1931E12C291BQ35184148-44A4BD45-0C5C-4798-B705-DCC8AF60D832Q35541293-AD97E064-3947-48A8-9345-2B164A810B2DQ35600416-65BDE7C5-1B56-41B7-ACE1-124698ECA241Q36156604-4D93734D-F4A9-4418-93E8-98682C927EE9Q36689356-82B1C806-219D-4125-979A-49753F9BD560Q36894417-CC79DD61-DA46-4DD4-8BCC-26B330A3A8CBQ37012066-BEE281EC-52DC-4FCD-B194-238AA21F8FC9Q37310816-630D35E5-474A-44FE-93EF-447E90196CBEQ37688886-7347EFE0-44BD-45A3-989B-CBD6CCDE40A4Q37773826-D8E5D91D-B684-43CD-97D4-123191D009D6Q37810956-3CC4EDD5-8120-4DD6-B96B-C27D19C02BF0Q37831912-D5DDB22B-44A5-49A9-8523-ADC3415BB962Q37979840-4B1E8D7D-5DF9-4D71-AC99-8608EED88159Q37984574-03EB9E94-FC26-4A13-A9B1-E6F55EA70D2AQ38208226-8D6255E4-2CB8-4FE6-AACB-246A74293467Q38253050-F13D54F2-3849-430C-875D-EDE0791E3F97Q38283308-1967C4D9-3733-4EB9-A599-883B79E1AA95Q38881198-53EF80F5-F5AE-43E8-8C54-5C3D1B410586Q42119910-9810E5D2-82FC-431D-923E-623C33E0DA49Q42689743-A7534CB9-C3F2-47EA-98A1-60E6FE028F06Q46447894-151C207B-A687-4CEF-94C6-680C14B16307Q47860105-AF9CEDCA-A9DE-4F1B-AA92-9350A07987C1Q53286733-0055C99C-BC06-4D50-B3F6-EC444B0B446BQ53356452-64AEB543-1E33-48AD-837B-D9349E21B752Q58696119-375B82FE-30C1-47BC-B417-FEF599D7CD11
P2860
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
@en
type
label
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
@en
prefLabel
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
@en
P2093
P2860
P356
P1476
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide.
@en
P2093
Beka Solomon
Eran Bosis
Gili Istrin
P2860
P304
P356
10.1002/JNR.20886
P577
2006-08-01T00:00:00Z